What is eGenesis?
Founded in 2015 and headquartered in Cambridge, Massachusetts, eGenesis is at the forefront of the biotechnology sector, specializing in gene editing and genome engineering. The company is primarily focused on the development of human transplantable organs, tissues, and cells, utilizing advanced CRISPR-based technologies to overcome the immunological barriers associated with xenotransplantation. By engineering porcine donors to be compatible with the human immune system, eGenesis aims to provide a sustainable and scalable solution to the global organ transplant crisis. Their market position is defined by a unique intersection of synthetic biology and clinical medicine, supported by a deep intellectual property portfolio and strategic partnerships with leading life science investors.
How much funding has eGenesis raised?
eGenesis has raised a total of $456M across 5 funding rounds:
Angel/Seed
$2M
Series A
$38M
Series B
$100M
Series C
$125M
Series D
$191M
Angel/Seed (2016): $2M, investors not publicly disclosed
Series A (2017): $38M led by Biomatics Capital, Khosla Ventures, Alexandria Equities, Alta Partners, Heritage Provider Network, and ARCH Venture Partners
Series B (2019): $100M supported by Arch Venture Partners, Fresenius Medical Care Ventures, Wellington Partners, Alta Partners, Biomatics Capital, Khosla Ventures, and Leaps by Bayer
Series C (2021): $125M featuring Samsara BioCapital, Polaris Partners Pte. Ltd, The Invus Group , LLC, Farallon Capital Management , L.L.C., and HBM Healthcare Investments AG
Series D (2024): $191M backed by Lux Capital, Khosla Ventures, and Arch Capital
Key Investors in eGenesis
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on a broad range of areas including health, AI, and robotics.
Biomatics Capital
Biomatics Capital is a for-profit venture firm focused on investing in transformative data-enabled innovations at the intersection of health care and technology.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists.
What's next for eGenesis?
With the successful closure of its latest funding round, eGenesis is poised to transition from a research-intensive entity into a clinical-stage powerhouse. The strategic allocation of these funds will likely prioritize the advancement of its lead programs through regulatory milestones and the expansion of its proprietary genome engineering infrastructure. As the company continues to refine its gene-editing techniques, the focus will shift toward establishing the safety and efficacy profiles required for human clinical trials. The ongoing support from a syndicate of top-tier venture capital firms provides the necessary runway to navigate the complex regulatory landscape of regenerative medicine and solidify its leadership in the future of organ transplantation.
See full eGenesis company page
